Carbonyl compounds generated and accumulated in the peritoneal dialysate
can be inactivated or eliminated by a carbonyl compound-trapping agent such as
aminoguanidine. Carbonyl compounds generated during sterilization and storage of
the peritoneal dialysate can be eliminated by pre-contacting with the trapping
agent. Further, it is possible to eliminate carbonyl compounds transferred from
the blood to the peritoneal cavity of the patient during peritoneal dialysis treatment,
by adding the trapping agent to the peritoneal dialysate or by circulating the
fluid through a carbonyl compound-trapping cartridge. Intraperitoneal protein modification
by carbonyl compounds is inhibited by the present invention, thereby sufficiently
reducing peritoneal disorders associated with peritoneal dialysis treatment.
